Quest Diagnostics understands that the COVID-19 pandemic has had a significant impact on higher education, and that distance learning doesn’t replace the value of campus life. That’s why we have created the Back to School program—a solution to help your students, faculty, and staff understand their risk so that they can stay focused on education.

The program combines prescreening with SARS-CoV-2 (COVID-19) antibody testing for an asymptomatic person and molecular testing for a symptomatic or high-risk person to provide insights into their COVID-19 status.

Knowing what comes next

Quest Diagnostics understands that the COVID-19 pandemic has had a significant impact on higher education, and that distance learning doesn’t replace the value of campus life. That’s why we have created the Back to School program—a solution to help your students, faculty, and staff understand their risk so that they can stay focused on education.

The program combines prescreening with SARS-CoV-2 (COVID-19) antibody testing for an asymptomatic person and molecular testing for a symptomatic or high-risk person to provide insights into their COVID-19 status.

Our Back to School solution can help you:

- Help your faculty, staff, students, and their parents understand their risk of exposure
- Make informed decisions about the risk to your faculty and staff
- Develop and implement return-to-campus scenarios
- Lessen the risk of exposure in your classrooms
- Help your students get the education and support they need to excel

“Return to an active on-campus environment will depend upon widespread testing, contact tracing, and isolation/quarantine of ill and exposed individuals both on campus and in the community.”

— American College Health Association Guidelines

For more information on COVID-19, please visit QuestDiagnostics.com/COVID19
A 3-phase model to help get and keep your students back on campus

1. **Returning to Campus**
   - Test faculty and administration staff with SARS-CoV-2 (COVID-19) antibody and molecular* tests
   - Screen students at home via an online questionnaire to determine the right test
   - Test high-risk, symptomatic, and exposed students with SARS-CoV-2 (COVID-19) molecular* tests via an at-home self collection kit or at a physician’s office
   - Test asymptomatic students with antibody tests at a Quest Patient Service Center, or with an in-home visit

2. **Staying on Campus**
   - Monitor for symptoms, provide ongoing testing, and quarantine any active cases on campus
   - Aggressively contact trace to limit the potential spread

3. **Coming back from breaks**
   - Rescreen at home prior to returning from breaks, and provide antibody and molecular testing to all qualifying students, as appropriate

To learn more about our Back to School program, contact your Quest Diagnostics sales representative or visit health.questdiagnostics.com/backtoschool

The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

- The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

**Reference**